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followed by semiautomated sequencing (using an ABI 377 sequencer;
Applied Biosystems, Weiterstadt, Germany), uncovered a novel
frameshift mutation in exon 2 of the DNA MMR gene hMLH1
(150insT; Fig 2). This mutation is predicted to lead to a premature
stop codon that results in a truncated, nonfunctional DNA repair
protein. In patients with MTS, only two different mutations in the
hMLH1 gene have been reported so far, whereas 12 mutations have
been identified in the hMSH2 gene (Kolodner et al, 1994; Liu et al,
1994; Kruse et al, 1996, 1998; Bapat et al, 1996).
In summary, a patient with an inherited DNA MMR defect
(HNPCC) was identified for the first time on the basis of a single
distinctive cutaneous tumor. Schwartz and Torre (1995) already
pointed out that there may be a hiatus of many years before both
elements – the sebaceous neoplasm and the internal cancer – are
present in a patient to allow the diagnosis of MTS. Our results
indicate that patients with isolated cystic sebaceous tumors are very
likely to have an inherited DNA MMR defect. For these patients
a lifelong surveillance for skin tumors and internal cancer of the
HNPCC spectrum should be recommended.
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meinschaft and of the Medical Faculty of the University of Bonn.
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Superantigens in T Cell Mediated Skin Diseases – More than a
Coincidence!
To the Editor
We read with interest the article by Jappe et al in the May 1998
issue of this journal, analyzing the frequency of superantigen-
producing Staphylococcus aureus isolates in patients suffering from
atopic dermatitis and nonatopic, healthy controls. The authors
found that 45% of strains from atopic dermatitis patients (n 5 22)
were capable of producing superantigens that did not exceed the
number of S. aureus strains isolated from healthy carriers capable
of superantigen production (n 5 8). Based on these findings,
the authors question the hypothesis that skin colonization with
superantigen-producing S. aureus is an essential prerequisite in the
pathogenesis of atopic dermatitis (Jappe et al, 1998).
We believe, however, that the design of the study is not suitable
to address this question. The authors analyzed the effect of a
defined environmental factor (staphylococcal superantigens) on two
different groups of individuals: one with a disease-prone genetic
background (i.e., atopy), the other one without this genetic
background. The fact that an environmental factor is not sufficient
to induce a disease in the absence of a disease-prone genetic
background, does not exclude its importance in the disease process.
Gliadin, for example, is tolerated by the large majority of individuals.
Nevertheless, in the presence of a defined genetic background, i.e.,
specific HLA class II DQ and DR alleles, gliadin causes celiac
disease (Howell et al, 1986; Lundin et al, 1994). If Jappe et al
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applied the same criteria to draw conclusions in the study of the
pathogenecity of gliadin, they would conclude that gliadin is not
an essential prerequisite in the pathogenesis of celiac disease.
This clearly emphasizes that besides defined (as in celiac disease)
or multifactorial (as in atopy) environmental triggers, the genetic
background is of major importance. With respect to psoriasis and
superantigens we recently demonstrated that superantigens do only
induce a psoriasiform dermatitis if the genetic background of psoriasis
is given, but not in healthy individuals (Boehncke et al, 1996). Addi-
tionally, in patients with the genetic background of atopy or psoriasis
we found that patients colonized with superantigen-producing S.
aureus strains suffer from a more severe disease compared with patients
that are colonized by S. aureus strains not capable of superantigen
production (Zollner et al, manuscript submitted).1
With respect to the study by Jappe et al, we think the authors
can only conclude that in the absence of the atopic background
bacterial superantigens are not sufficient to induce (atopic) derma-
titis. No conclusion should be drawn on the relevance of super-
antigens in atopic dermatitis.
Thomas M. Zollner, Roland Kaufmann
Department of Dermatology, University of Frankfurt Medical
School, Frankfurt, Germany
1Zollner TM, Wichelhaus T, Duijvestijn AM, Boehncke W-H, Brade
V, Kaufmann R: Production of superantigens by S. aureus is of clinical
relevance in patients suffering from psoriasis and atopic eczema. J Invest
Dermatol 109:445, 1997 (abstract 248).
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Reply
Our answer to the Letter entitled ‘‘Superantigens in T cell mediated
skin diseases – more than a coincidence!’’ is rather simple and goes
back to criteria established already by Robert Koch for the
attribution of a particular disease to a particular microbial pathogen.
Staphylococcus aureus was not detected in 37% of the study group
and therefore this microorganism could not account for atopic
dermatitis in these patients (Jappe et al, 1998). Furthermore, only
45% of the S. aureus isolates from the 63% of the study group
carrying this microorganism on their skin had the genotype for the
In Vitro Determination of Erythema and Immunologic
Protection Afforded by Sunscreens do not Accord with In Vivo
Assessments
To the Editor:
As members of the cosmetic industry involved in sunscreen research
and development, and currently working on photoimmunologic
protection afforded by sunscreens, we would like to add our
comments to those from Gasparro (1998) and Wolf and Kripke
(1998) on Davenport et al’s publication (1997), particularly after
reading Chu et al’s (1998) responses to these comments.
The statement ‘‘sunscreens protect against immunosuppression
beyond their designated sun protection factor (SPF)’’ is incorrect.
Re-analysis of the data shows exactly the opposite. In addition, we
want to state that SPF determined in vitro by the Diffey method
often do not correlate with the in vivo SPF (Diffey and Farr, 1991).
For example, based on our extensive experience, sunscreen A (2%
octyl-methoxy cinnamate) would be expected to have an in vivo
SPF around 2 (5.7 found in vitro), sunscreen B (2% o-PABA) a SPF
of 2.5 (4.5 found in vitro), and sunscreen E (6% ZnO) a SPF of 5
(3.8 found in vitro). So, the conclusion that cream A, which
provided the highest immune protection, is the cream that had the
highest in vitro SPF is valid only for an in vitro situation and this
model of evaluation.
We also disagree with one of the other conclusions of this work:
‘‘Protection by creams D and E, broad-spectrum sunscreens, is
lower than protection afforded by pure UVB sunscreens (creams
A and B).’’ Indeed, the published in vivo results issued from our
laboratory and from other international teams have demonstrated
just the opposite: sunscreens containing both UVA and UVB filters
are more effective against photoimmunosuppression than pure
Manuscript received September 23, 1998; accepted for publication
September 25, 1998.
superantigens analyzed. This would clearly indicate that these
superantigens were not involved in the pathology. The design of
the investigation does allow the hypothesis of cause and effect, S.
aureus and atopic dermatitis, to be tested. Assuming that genetic
disposition of the individual is essential combined with an extraneous
environmental factor, in this case S. aureus superantigen producer,
then atopic dermatitis would occur only when S. aureus was present
on the skin. The hypothesis that S. aureus skin colonization is a
prerequisite for atopic dermatitis is greatly weakened by our
data. This investigation strengthens the hypothesis that other
environmental factors, apart from S. aureus, are important in atopic
dermatitis.
Uta Jappe, Dagmar Heuck,* Wolfgang Witte,* Harald Gollnick
Department of Dermatology, Otto-von-Guericke University of
Magdeburg, Magdeburg, Germany
*Robert-Koch Institute, National Staphylococcal Reference
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UVB formulations (Bestak et al. 1995; Damian et al. 1997, Serre
et al. 1997, Gueniche and Fourtanier, 1997; Moyal, 1998). We
have also demonstrated that the higher the UVA protection level,
the better the immune system is protected, and that sunscreen
protection factor against immunosuppression are lower than their
in vivo SPF.
Anny Fourtanier
Department of Dermato-Biology, L’Oreal-Advanced Research-
Life Sciences Research-92583, Clichy Cedex, France
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